Nxera Pharma

4565.TPhase 3

nxera-pharma.co.jp

Nxera Pharma is a Tokyo-listed biopharma company that rebranded from Sosei Group in 2023 to reflect its evolution into a fully integrated R&D and commercial entity. Its core strategy is built on a GPCR-focused technology platform, strategic partnerships with major pharmaceutical companies, and a pipeline targeting high-need areas in CNS and immunology. The company aims to become a leading, innovation-driven biopharma player in the Asia-Pacific region and globally.

Market Cap

$499.3M

Employees

400-500

Focus

Biotech

4565.T · Stock Price

USD 879.00598.00 (-40.49%)

Historical price data

AI Company Overview

Technology Platform

Proprietary StaR® technology platform for structure-based drug design targeting G protein-coupled receptors (GPCRs), enabling the discovery of novel small molecules and biologics.

Pipeline Snapshot

16 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Daridorexant + Placebo	Insomnia Disorder	Phase 3
HTL0018318 + Placebo	Dementia With Lewy Bodies	Phase 2
HTL0039732 Capsules + HTL0039732 Capsules and atezolizumab infusion	Neoplasms	Phase 1/2
HTL0014242 + Placebo oral capsule	Healthy	Phase 1
HTL0009936 modified release + HTL0009936 immediate release	Alzheimer's Disease	Phase 1

Funding History

Total raised: $100M

PIPE$100MUndisclosedOct 15, 2023

IPOUndisclosedUndisclosedDec 15, 2002

Opportunities

Near-term commercialization of Fexuprazan in Japan provides a path to direct product revenue.

Advancing internal immuno-oncology (EP4) and immunology (GPR35) programs into the clinic can build a valuable proprietary pipeline.

The prolific GPCR platform continues to offer opportunities for new high-value partnerships.

Risk Factors

High risk of clinical failure for novel neurological candidates.

Heavy reliance on the success of strategic partners for major pipeline assets.

Execution risk associated with launching its first proprietary product in Japan.

Competitive Landscape

Competes in GPCR drug discovery with platform biotechs like Confo Therapeutics and Domain Therapeutics. In neuroscience, faces competition from Karuna (BMS), Cerevel, and Neurocrine. Its key differentiation is its validated, industry-leading StaR® platform and a proven track record of generating clinical candidates for partners.

Publications

Pipeline